OOIR: Observatory of International Research

Papers

(The TQCC of Drug Resistance Updates is 27. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-07-01 to 2024-07-01.)

Article	Citations
Tumor microenvironment and epithelial mesenchymal transition as targets to overcome tumor multidrug resistance	284
An update on drugs with therapeutic potential for SARS-CoV-2 (COVID-19) treatment	183
Anticancer drug resistance: An update and perspective	146
Taxanes in cancer treatment: Activity, chemoresistance and its overcoming	145
The role of alternative splicing in cancer: From oncogenesis to drug resistance	131
Multidrug resistance proteins (MRPs): Structure, function and the overcoming of cancer multidrug resistance	117
Antimicrobial peptides for combating drug-resistant bacterial infections	115
Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification	115
Cancer immunotherapy resistance based on immune checkpoints inhibitors: Targets, biomarkers, and remedies	112
Therapeutic strategies to overcome taxane resistance in cancer	111
FDA approved drugs with pharmacotherapeutic potential for SARS-CoV-2 (COVID-19) therapy	111
Novel nanomedicines to overcome cancer multidrug resistance	107
Hypoxia as a driver of resistance to immunotherapy	107
Inhibiting the inhibitors: Targeting anti-apoptotic proteins in cancer and therapy resistance	89
A review on antimicrobial botanicals, phytochemicals and natural resistance modifying agents from Apocynaceae family: Possible therapeutic approaches against multidrug resistance in pathogenic microor	82
Current status of antivirals and druggable targets of SARS CoV-2 and other human pathogenic coronaviruses	79
Nanomedicine to target multidrug resistant tumors	75
Overcoming anti-cancer drug resistance via restoration of tumor suppressor gene function	66
Overcoming cancer chemotherapy resistance by the induction of ferroptosis	64
Repurposing old drugs to fight multidrug resistant cancers	62
New insights into antiangiogenic therapy resistance in cancer: Mechanisms and therapeutic aspects	58
New insights into the pharmacological, immunological, and CAR-T-cell approaches in the treatment of hepatocellular carcinoma	55
Research progress of therapeutic effects and drug resistance of immunotherapy based on PD-1/PD-L1 blockade	54
Metal- and metalloid-based compounds to target and reverse cancer multidrug resistance	54
Current therapy and drug resistance in metastatic castration-resistant prostate cancer	53

Thirty years of VRE in Germany – “expect the unexpected”: The view from the National Reference Centre for Staphylococci and Enterococci	49
Cancer-associated fibroblasts suppress ferroptosis and induce gemcitabine resistance in pancreatic cancer cells by secreting exosome-derived ACSL4-targeting miRNAs	49
GSK3β as a novel promising target to overcome chemoresistance in pancreatic cancer	49
Long non-coding RNA mediated drug resistance in breast cancer	48
ABC transporters affects tumor immune microenvironment to regulate cancer immunotherapy and multidrug resistance	48
The key roles of the lysine acetyltransferases KAT6A and KAT6B in physiology and pathology	47
Impact of cancer metabolism on therapy resistance – Clinical implications	47
Overcoming PARPi resistance: Preclinical and clinical evidence in ovarian cancer	46
Microenvironment-driven intratumoral heterogeneity in head and neck cancers: clinical challenges and opportunities for precision medicine	46
COVID-19 update: The race to therapeutic development	44
Targeting multidrug resistance-associated protein 1 (MRP1)-expressing cancers: Beyond pharmacological inhibition	43
Cross-resistance and drug sequence in prostate cancer	41
N6-methyladenosine-modified circular RNA QSOX1 promotes colorectal cancer resistance to anti-CTLA-4 therapy through induction of intratumoral regulatory T cells	40
Sunitinib resistance in renal cell carcinoma: From molecular mechanisms to predictive biomarkers	39
Loss of cancer-associated fibroblast-derived exosomal DACT3-AS1 promotes malignant transformation and ferroptosis-mediated oxaliplatin resistance in gastric cancer	39
Metallothionein isoforms as double agents – Their roles in carcinogenesis, cancer progression and chemoresistance	38
Exosomal circular RNAs: A chief culprit in cancer chemotherapy resistance	38
Emerging role of autophagy in anti-tumor immunity: Implications for the modulation of immunotherapy resistance	37
Regulation of cisplatin resistance in bladder cancer by epigenetic mechanisms	36
Selenium and tellurium in the development of novel small molecules and nanoparticles as cancer multidrug resistance reversal agents	35
The Omicron variant of concern: Diversification and convergent evolution in spike protein, and escape from anti-Spike monoclonal antibodies	35
Exosomal LOC85009 inhibits docetaxel resistance in lung adenocarcinoma through regulating ATG5-induced autophagy	34
In vitro biomimetic models for glioblastoma-a promising tool for drug response studies	32
Molecular Modeling Strategies of Cancer Multidrug Resistance	32
Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma	32
The role of extracellular vesicles in the transfer of drug resistance competences to cancer cells	31
The strategic roles of four enzymes in the interconnection between metabolism and oncogene activation in non-small cell lung cancer: Therapeutic implications	30
Resistance-proof antimicrobial drug discovery to combat global antimicrobial resistance threat	29
Paclitaxel resistance related to nuclear envelope structural sturdiness	29
Nanotechnology-based approaches overcome lung cancer drug resistance through diagnosis and treatment	28
Precision medicine: Ray of hope in overcoming cancer multidrug resistance	27